Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

175 women of reproductive age, with hirsutism of differing degrees and different pathogenetic causes (ovarian, adrenal, iatrogenic) or idiopathic, and acne were treated with two different combinations of Cyprotrone acetate and ethinyl estradiol (SH 8.1041 and SH B209AB). 90 patients were given SH 8.1041 and 10 were given SH B209AB. 75 received both preparations. The total number of treatment cycles was 1534. Clinical, hormonal and biochemical assessments were made before, during and after treatment. The degrees of hirsutism and acne, and of seborrhea and hair loss when present, were scored by means of a modified version of the Ferriman and Gallway criteria. SH 8.1041 brought about a significant improvement in the majority of the patients. SH B209AB was generally used as maintenance therapy for hirsutism and severe acne. It was the initial treatment of choice in patients with milder acne. Reduction of hirsutism was usually apparent after the fourth cycle of therapy and acne regressed after the first month. Both combinations were well-tolerated biochemically. In a few patients on SH 8.1042, slight and transient increases in BSP, SGOT, SGPT and bilirubin were observed, but cessation of treatment was not necessary. Some patients on SH 8.1041 complained of transient frigidity, mild depression, breast discomfort and nausea.
 ...
PMID:Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol. 14 May 76

2 types of combined estrogen-progestogen oral contraceptives (OCs) were administered to 40 women for 3 cycles. The women were selected on the basis of willingness to participate and attend the clinic at monthly intervals as well as absences of contraindications to contraceptive steroid therapy. 32 of the women had a family income below Rs. 250/month, 15 had below Rs. 100/month, all at poverty level. Group A was given a combination of Lynestrenol 2.5 mg with Mestranol 0.75 mg (Noracycline 2.5) from day 5 to day 26 of each of 3 cycles. Group B was given Megestrol acetate 4 mg with 0.05 mg ethinyl estradiol from day 5 to day 26 of each of 3 cycles (both groups were equally divided into 20 women each). The women reported for follow-up between 22-25 days of each cycle. Blood samples were collected in 4 consecutive cycles (1st cycle was a control) and analyzed. Side effects such as nausea, vomiting, bleeding, and measures of blood pressure and weight were recorded. No significant differences were noted in mean transominases, bilirubin levels, serum proteins, or albuminium/globulin ratio and all were in normal ranges. The women's weights ranged from 26-50 kg and hemoglobin values from 9.6-12 gm. In other tests performed with low dosages of progestogens (0.5-2.5 mg) and estrogens (0.05-0.075 mg) no biochemical evidence of liver dysfunction was found except a slightly higher percentage of raised BSP retention in some series. Though gross abnormalities were not observed in commonly used parameters of liver function, it is suggested that previous liver disease with residual damage or history of idiopathic jaundice with pregnancy should be contraindications for use of these drugs. Dosage used should be minimum, compatible with efficacy for both the estrogens and the progestogens.
 ...
PMID:Metabolic effects of contraceptive steroids IV. Liver function tests--short term observations. 1231 Apr 10